mProX™ Human BLK Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1036	Magic™ Human BLK in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

BLK

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

Ba/F3; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Autoimmune Research; Diabetes Research

Related Diseases

Maturity-Onset Diabetes Of The Young, Type 11 and Systemic Lupus Erythematosus. Among its related pathways are Gene expression (Transcription) and MAPK-Erk Pathway

Gene ID

640

UniProt ID

P51451

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

A protein coding gene is called BLK (BLK Proto-Oncogene, Src Family Tyrosine Kinase). Maturity-Onset Diabetes of the Young, Type 11, and Systemic Lupus Erythematosus are among the illnesses linked to BLK. The MAPK-Erk Pathway and gene expression (transcription) are two of its associated pathways. This gene's Gene Ontology (GO) annotations include protein tyrosine kinase activity, transferase activity, and transferring phosphorus-containing groups. HCK is a significant paralog of this gene. The customized BLK stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Queena

The BLK cell line has been crucial in elucidating the receptor's role in various biological processes. Mar 16 2023

chat Verified Customer

chat Vanessa

The BLK cell line is easy to use and has become an essential tool in my lab. May 02 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Blk(Y501F) drives resistance to apoptosis and cytokine-independent proliferation.

IL-3 was not present throughout the culture of non-transfected Ba/F3 cells (NT), Ba/F3 Blk-wt, and Ba/F3 Blk(Y501F). The proportion of viable cells at various times is shown in the graph on the left, where each data point is the mean of a count of duplicate samples. The total number of live cells is represented on the graph to the right.

Ref: Petersen, D. L., et al. "B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)." Leukemia 28.10 (2014): 2109-2112.

Pubmed: 24919804

DOI: 10.1038/leu.2014.192

Research Highlights

Many tyrosine kinases, including receptor and nonreceptor kinds, are involved in the etiology and medication resistance of almost all forms of leukemia in malignant hemopoiesis. Scientific literature has examined ABL1 kinase mutations and their pharmacological inhibitors in great detail.
K. Bhanumathy, Kalpana, et al. "Protein tyrosine kinases: their roles and their targeting in leukemia." Cancers 13.2 (2021): 184.
Pubmed: 33430292 DOI: 10.3390/cancers13020184

The non-receptor tyrosine kinase B-lymphoid tyrosine kinase (BLK) is a member of the SRC family of kinases. B-cell development and B-cell receptor signaling are known to be functionally impacted by BLK. According to recent data, B-lymphoid tyrosine kinase may be a possible oncogene in cutaneous T-cell lymphoma and other T-cell cancers, where it is expressed ectopically.
Petersen, David Leander, et al. "A novel BLK-induced tumor model." Tumor Biology 39.7 (2017): 1010428317714196.
Pubmed: 28670978 DOI: 10.1177/1010428317714196